Flagship Pioneering, the US-based life sciences venture firm behind over 40 biotech companies, has entered into a five-year research partnership with the Yong Loo Lin School of Medicine at the National University of Singapore (NUS Medicine), National University Hospital (NUH), and the National University Health System (NUHS), aimed at accelerating medical innovation and improving patient outcomes.

Under a newly signed Memorandum of Understanding (MOU), the collaboration will focus on advancing research projects that leverage Flagship’s extensive biotech network and Singapore’s clinical and academic strengths.

Beyond scientific research, the partnership will also nurture future talent. Students and scientists from NUS Medicine are set to benefit from internships, secondments and the Flagship Fellowship programme, offering them hands-on exposure and mentorship opportunities in Flagship’s global ecosystem.

A key component of the collaboration will see Flagship tapping into NUHS and NUH’s vast clinical data to uncover new biological insights, test hypotheses and translate discoveries into impactful patient treatments.

André Andonian, Chair of Asia Pacific and Strategic Advisor at Flagship Pioneering, said Singapore will serve as a crucial hub for the firm’s ambitions in the region.

“Our collaboration will help expand the global reach and impact of Flagship and its companies, while anchoring life science innovation in Singapore and Asia Pacific,” he said. “Together with NUS Medicine, NUH and NUHS, we aim to advance breakthroughs that impact patients and the planet.”

NUS Medicine Dean Professor Chong Yap Seng emphasised the partnership’s potential to bridge research and clinical practice.

“As part of NUHS, NUS Medicine and NUH are uniquely placed to translate biomedical research into clinical solutions,” he said. “Through this collaboration, we hope to deliver practice-changing innovations that will benefit patients and communities worldwide.”

The move adds to Flagship’s growing presence in Singapore, complementing its earlier partnership with the Agency for Science, Technology and Research (A*STAR), as it strengthens ties within the country’s burgeoning biotech ecosystem.